Benzinga’s Top Ratings Upgrades, Downgrades For December 28, 2022
Upgrades See all analyst ratings upgrades. Downgrades See all analyst ratings downgrades. Initiations Capital One initiated coverage on…
IDEAYA Biosciences Announces Submission Of IND Application To The U.S. FDA For PARG Development Candidate IDE161
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has submitted an Investigational
Baird Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $24
Baird analyst Joel Beatty maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $18 to $24.
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In For Multiple Combination Cohorts In MTAP-Deletion Tumors
First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors
First patient dosed in IDE397 combination with taxane in
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday’s Mid-Day Session
Gainers
HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A.
Arconic, Rhythm Pharmaceuticals And Some Other Big Stocks Moving Lower In Today’s Pre-Market Session
U.S. stock futures traded higher this morning ahead of several economic reports. Here are some big stocks recording losses in today’s pre-market trading session.
IDEAYA Priced ~7.62M Share Public Offering of Common Stock @$10.50/Share
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an underwritten public offering of 7,619,048 shares of its common stock at a public offering price of $10.50 per share, before underwriting discounts and commissions.